X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1226) 1226
Publication (68) 68
Book Review (23) 23
Book / eBook (8) 8
Newsletter (5) 5
Book Chapter (3) 3
Dissertation (3) 3
Conference Proceeding (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (813) 813
male (650) 650
animals (551) 551
cardiotonic agents - pharmacokinetics (500) 500
pharmacology & pharmacy (435) 435
index medicus (412) 412
cardiotonic agents - pharmacology (398) 398
female (366) 366
cardiotonic agents - therapeutic use (365) 365
cardiotonic agents - administration & dosage (312) 312
pharmacokinetics (248) 248
rats (235) 235
middle aged (226) 226
adult (218) 218
heart failure - drug therapy (213) 213
digoxin - pharmacokinetics (192) 192
cardiotonic agents - blood (185) 185
aged (176) 176
digoxin (148) 148
cardiac & cardiovascular systems (147) 147
drug interactions (139) 139
dose-response relationship, drug (135) 135
cardiotonic agents - adverse effects (127) 127
heart failure (125) 125
hemodynamics - drug effects (121) 121
administration, oral (118) 118
cardiotonic agents (114) 114
heart (102) 102
digoxin - blood (99) 99
myocardium - metabolism (98) 98
heart rate - drug effects (97) 97
rats, sprague-dawley (91) 91
myocardial contraction - drug effects (89) 89
mice (83) 83
dogs (81) 81
time factors (81) 81
cardiac glycosides (80) 80
infusions, intravenous (80) 80
milrinone (80) 80
blood pressure - drug effects (77) 77
drugs (77) 77
half-life (77) 77
heart - drug effects (76) 76
digoxin - administration & dosage (75) 75
rodents (73) 73
dopamine (72) 72
drug therapy (72) 72
metabolism (72) 72
research (72) 72
treatment outcome (70) 70
dobutamine (69) 69
cardiotonic agents - metabolism (68) 68
biological availability (67) 67
injections, intravenous (67) 67
heart-failure (66) 66
pyridazines - pharmacokinetics (66) 66
area under curve (64) 64
kinetics (64) 64
health aspects (63) 63
heart failure - physiopathology (63) 63
double-blind method (62) 62
tissue distribution (61) 61
biochemistry & molecular biology (60) 60
cardiotonic agents - chemistry (60) 60
cardiovascular agents (60) 60
ischemia (59) 59
oxidative stress (59) 59
pyridazines - therapeutic use (59) 59
rats, wistar (59) 59
in vitro techniques (58) 58
levosimendan (58) 58
analysis (57) 57
p-glycoprotein (57) 57
toxicology (57) 57
cross-over studies (55) 55
disease models, animal (55) 55
mortality (54) 54
hydrazones - therapeutic use (53) 53
physiological aspects (53) 53
anesthesiology (52) 52
care and treatment (52) 52
pharmacology (52) 52
physiology (52) 52
adolescent (51) 51
dosage and administration (49) 49
myocardium - pathology (49) 49
pyridazines - pharmacology (49) 49
bioavailability (47) 47
hemodynamics (47) 47
cardiotonics (46) 46
digoxin - therapeutic use (45) 45
medicine, general & internal (45) 45
peripheral vascular disease (45) 45
cardiopulmonary bypass (44) 44
heart diseases (44) 44
hydrazones - pharmacokinetics (44) 44
infant, newborn (44) 44
medicine (44) 44
models, biological (44) 44
digoxin - adverse effects (43) 43
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1171) 1171
German (27) 27
Russian (9) 9
Japanese (8) 8
Spanish (6) 6
Chinese (5) 5
French (5) 5
Czech (2) 2
Italian (2) 2
Danish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 04/2015, Volume 353, Issue 1, pp. 9 - 16
Proanthocyanidins are among the most abundant constituents in pine bark extracts (PBEs). This review summarizes medical research on PBEs from Pinus pinaster,... 
ANTIOXIDANT ACTIVITY | PROCYANIDIN-RICH EXTRACT | OXIDATIVE DAMAGE | DNA-DAMAGE | FRENCH MARITIME PINE | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | DIFFERENTIATION-RELATED PROTEIN | RADIATA BARK | ENDOTHELIAL FUNCTION | RAT PLASMA | Plant Extracts - toxicity | Plant Extracts - pharmacology | Humans | Plant Bark - chemistry | Anticarcinogenic Agents - pharmacokinetics | Antineoplastic Agents - toxicity | Immunologic Factors - pharmacokinetics | Neuroprotective Agents - pharmacology | Cardiotonic Agents - toxicity | Neuroprotective Agents - pharmacokinetics | Proanthocyanidins - pharmacology | Anticarcinogenic Agents - toxicity | Immunologic Factors - toxicity | Anti-Inflammatory Agents - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Proanthocyanidins - pharmacokinetics | Anticarcinogenic Agents - pharmacology | Pinus - chemistry | Anti-Inflammatory Agents - pharmacology | Anti-Inflammatory Agents - toxicity | Cardiotonic Agents - pharmacokinetics | Neuroprotective Agents - toxicity | Antioxidants - pharmacology | Cardiotonic Agents - pharmacology | Antioxidants - toxicity | Animals | Plant Extracts - pharmacokinetics | Lipid Metabolism - drug effects | Proanthocyanidins - toxicity | Antioxidants - pharmacokinetics | Immunologic Factors - pharmacology | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 2/2012, Volume 29, Issue 2, pp. 163 - 177
Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with type 2 diabetes mellitus (T2DM). The... 
dapagliflozin | pharmacodynamics | Rheumatology | simvastatin | sodium glucose co-transporter-2 | Internal Medicine | Oncology | digoxin | warfarin | type 2 diabetes | Medicine & Public Health | pharmacokinetics | valsartan | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SELECTIVE SGLT2 INHIBITOR | HEALTHY-SUBJECTS | HUMANS | INADEQUATE GLYCEMIC CONTROL | DIABETES-MELLITUS | POTENT | HYPERGLYCEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TYPE-2 | ASSOCIATION | Hypoglycemic Agents - pharmacokinetics | Benzhydryl Compounds | Valsartan | Valine - pharmacokinetics | Humans | Middle Aged | Valine - analogs & derivatives | Male | Glucosides - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Anti-Arrhythmia Agents - pharmacokinetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | Anticholesteremic Agents - pharmacokinetics | Drug Interactions | Adult | Female | Anticoagulants - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Tetrazoles - pharmacokinetics | Type 2 diabetes | Warfarin | Digoxin | Simvastatin | Drug interactions | Anticoagulants (Medicine) | Glucose | Dextrose | Antilipemic agents | Cardiac glycosides | Blood circulation disorders | Cardiotonic agents | Cardiac patients | Diabetes | Heart diseases
Journal Article
Blood, ISSN 0006-4971, 12/2012, Volume 120, Issue 26, pp. 5217 - 5223
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2014, Volume 54, Issue 7, pp. 800 - 808
Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic (PD) drug–drug interactions... 
pharmacokinetics | interaction | digoxin | pharmacodynamics | warfarin | PHARMACOLOGY & PHARMACY | Acetates - adverse effects | Acetates - blood | Digoxin - adverse effects | Enzyme Inhibitors - blood | Humans | Middle Aged | Prothrombin Time | Aminopyridines - pharmacokinetics | Aminopyridines - adverse effects | Half-Life | Warfarin - adverse effects | Male | Metabolic Clearance Rate | Diacylglycerol O-Acyltransferase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Hypolipidemic Agents - blood | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Cardiotonic Agents - adverse effects | Adult | Female | Digoxin - blood | Enzyme Inhibitors - adverse effects | Aminopyridines - administration & dosage | Hypolipidemic Agents - adverse effects | Reproducibility of Results | Cardiotonic Agents - pharmacokinetics | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | International Normalized Ratio | Acetates - administration & dosage | Aminopyridines - blood | Cardiotonic Agents - blood | Warfarin - blood | Adolescent | Hypolipidemic Agents - administration & dosage | Hypolipidemic Agents - pharmacokinetics | Acetates - pharmacokinetics | Cohort Studies | Warfarin | Dosage and administration | Digoxin | Pharmacokinetics | Analysis | Drug interactions | Prescription drugs
Journal Article
Acta Pharmacologica Sinica, ISSN 1671-4083, 2018, Volume 40, Issue 5, pp. 699 - 709
The combinational administration of antioxidants and chemotherapeutic agents during conventional cancer treatment is among one of the most controversial areas... 
cardioprotection | doxorubicin | antioxidants | chemotherapeutic efficacy | glutathione | hepatoprotection | VITAMIN-C | RISK | CARDIOTOXICITY | CHEMISTRY, MULTIDISCIPLINARY | CANCER-THERAPY | CHEMOTHERAPY | LUNG-CANCER | ANTIOXIDANT STATUS | PHARMACOLOGY & PHARMACY | ANTHRACYCLINES | SUPEROXIDE-DISMUTASE | CARDIAC MITOCHONDRIA | Glutathione - pharmacokinetics | Doxorubicin - therapeutic use | Humans | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - toxicity | Cardiotonic Agents - therapeutic use | Tissue Distribution | Heterografts | Myocardium - metabolism | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Cardiotoxicity - prevention & control | Doxorubicin - administration & dosage | Chemical and Drug Induced Liver Injury - prevention & control | Glutathione - therapeutic use | Cardiotonic Agents - pharmacokinetics | Liver - metabolism | Rats | Contraindications, Drug | Doxorubicin - pharmacokinetics | Doxorubicin - toxicity | Antioxidants - therapeutic use | Animals | Cardiotonic Agents - administration & dosage | Glutathione - administration & dosage | Mice, Nude | Antioxidants - administration & dosage | Cell Line, Tumor | Mice, Inbred BALB C | Antioxidants - pharmacokinetics | Heart | Cell culture | Animal models | Pharmacodynamics | Effectiveness | Toxicity | Tumor cells | Liver | Pharmacology | Doxorubicin | Anticancer properties | Antioxidants | Chemotherapy | Rodents | Biocompatibility | Mice | In vivo methods and tests | Pharmacokinetics | Hepatotoxicity | Glutathione | Cancer | Tumors
Journal Article
Journal of Nephrology, ISSN 1121-8428, 12/2014, Volume 27, Issue 6, pp. 659 - 666
The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney... 
Nephrology | Phase I | Medicine & Public Health | Urology/Andrology | Hyperphosphatemia | Chronic kidney disease | Pharmacokinetics | Sucroferric oxyhydroxide | MORTALITY | PHOSPHORUS | PHOSPHATE BINDER | BIOAVAILABILITY | INDIVIDUALS | DIALYSIS PATIENTS | PA21 | CALCIUM | UROLOGY & NEPHROLOGY | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | Digoxin - adverse effects | Diuretics - pharmacokinetics | Chelating Agents - administration & dosage | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Warfarin - administration & dosage | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Cardiotonic Agents - adverse effects | Diuretics - blood | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Risk Assessment | Furosemide - pharmacokinetics | Cardiotonic Agents - pharmacokinetics | Omeprazole - administration & dosage | Sucrose - adverse effects | Anticoagulants - adverse effects | Anticoagulants - blood | Cardiotonic Agents - administration & dosage | Models, Biological | Ferric Compounds - adverse effects | Losartan - administration & dosage | Diuretics - adverse effects | Furosemide - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Anticoagulants - administration & dosage | Area Under Curve | Losartan - blood | Omeprazole - blood | Warfarin - adverse effects | Ferric Compounds - administration & dosage | Healthy Volunteers | Furosemide - adverse effects | Adult | Female | Proton Pump Inhibitors - blood | Digoxin - blood | Losartan - pharmacokinetics | Chelating Agents - adverse effects | Furosemide - blood | Sucrose - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Models, Statistical | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Proton Pump Inhibitors - pharmacokinetics | Digoxin - administration & dosage | Cardiotonic Agents - blood | Warfarin - blood | Losartan - adverse effects | Anticoagulants - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Original
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 11/2015, Volume 12, Issue 11, pp. 4166 - 4173
Like other GLP-1 receptor agonists used for treatment of type 2 diabetes, liraglutide delays gastric emptying. In this clinical absorption study, the primary... 
liraglutide | gastrointestinal absorption | GLP-1 receptor agonist | drug interaction | biopharmaceutical classification system | MEDICINE, RESEARCH & EXPERIMENTAL | HUMAN GLP-1 ANALOG | EXENATIDE | OPEN-LABEL | PHARMACODYNAMICS | BIOAVAILABILITY | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOKINETICS | TOLERABILITY | DIGOXIN | PHARMACOLOGY & PHARMACY | GASTRIC-ACID SECRETION | biopharmaceutical classification systems | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Atorvastatin Calcium - administration & dosage | Humans | Middle Aged | Lisinopril - pharmacokinetics | Antihypertensive Agents - administration & dosage | Male | Tissue Distribution | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Drug Interactions | Griseofulvin - pharmacokinetics | Liraglutide - pharmacology | Antifungal Agents - pharmacokinetics | Computer Simulation | Adult | Female | Griseofulvin - administration & dosage | Lisinopril - administration & dosage | Atorvastatin Calcium - pharmacokinetics | Gastrointestinal Absorption | Double-Blind Method | Administration, Oral | Cardiotonic Agents - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Gastric Emptying | Digoxin - pharmacokinetics | Hypoglycemic Agents - pharmacology | Cross-Over Studies | Cardiotonic Agents - administration & dosage | Digoxin - administration & dosage | Adolescent | Antifungal Agents - administration & dosage | Biopharmaceutics - classification | Therapeutic Equivalency | Pharmaceutical Sciences | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Farmaceutiska vetenskaper
Journal Article
Journal Article